GLP-3 60MG

Description

GLP-3 60mg — retatrutide research peptide, Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

The 60mg vial is the high-content format of retatrutide (LY3437943) in this catalogue, where the compound is listed under the shop name GLP-3. Retatrutide is a single 39-amino-acid synthetic peptide acting on the GIP, GLP-1 and glucagon receptors^[1]; its first phase 3 trials were published in 2026^{[2, 3]}, and it remains an investigational drug without approval from any regulator. Larger vials suit laboratories that run many assays from one lot — the material is still research-grade lyophilized peptide for laboratory use only.

Full research overview, study table & references → GLP-3 (retatrutide) in Canada: research guide

Identity at a glance

Batch documentation

A batch-specific COA for this strength has not been posted yet — see the COA library (/coa/). The library’s retatrutide report was generated on a 10 mg vial batch; a 60 mg lot is a different preparation and that report is not shown here. When a 60 mg batch report is issued it will be embedded on this page.

What researchers have looked at

• Phase 3, type 2 diabetes (2026, 537 adults, 40 weeks): HbA1c fell more than with placebo across the doses tested; the most frequent adverse events were mild-to-moderate gastrointestinal events that subsided with time, discontinuations for adverse events ran 2–5% versus none on placebo, no severe hypoglycaemia occurred, and two deaths were judged unrelated to the drug^[2].
• Phase 3, obesity with type 2 diabetes (2026, 1,152 adults, 80 weeks, eight countries): body weight fell dose-dependently versus placebo; 84% completed study drug^[3].
• Diet-induced obese MASH mouse and hamster models (2026): lower body weight, fat and lean mass, insulin-resistance index, hepatic steatosis score and lipids in mice; altered food preference and halved hepatic triglyceride in hamsters without a change in histopathology score^[4].
• Renal fibrosis (2026, HK-2 cells; UUO and aged mice): retatrutide’s effects were linked to inhibition of both PI3K-AKT and NF-κB pathways, with the largest effect of the three incretin drugs compared, at the doses tested^[5].
• Anti-doping and the grey market (2026): an LC-HRMS method validated to WADA criteria detected retatrutide in plasma and urine of self-administering users^[6]; a case report describes a man with type 1 diabetes admitted with impending ketoacidosis after an online-purchased “retatrutide” product^[7].

None of these results transfers to the vial sold here. They are cited to describe the compound’s literature, including its risks, not to suggest an effect of this product.

Storage and handling

• A 60mg vial will usually be drawn on over several experiments: store it sealed at −20 °C (site guidance: stable up to 24 months as lyophilized powder), let it reach room temperature before opening to avoid condensation, and return it promptly. Short holds may be cool, dry and dark.
• Prepare working solutions in small volumes rather than dissolving the whole vial; lipidated peptides aggregate readily once in solution. Reconstitution and handling protocols are the researcher’s own and are not described here.

Smaller formats: GLP-3 (RT) 5MG · GLP-3 (RT) 10MG (posted COA) · GLP-3 (RT) 20MG · GLP-3 pen. Shipping is from inside Canada by Canada Post; the shipping policy covers cut-off, delivery times and the free-shipping threshold. The whole catalogue is on the page where you can buy peptides online in Canada.

Frequently asked questions

Can I buy GLP-3 60mg in Canada?

Yes. Shop Peptides Online lists the 60mg vial of retatrutide (catalogue name GLP-3) as research-grade lyophilized peptide, shipped from inside Canada by Canada Post. It is sold for laboratory research only.

What is the 60mg vial for?

It is the largest retatrutide strength in this catalogue, intended for laboratories running larger analytical or in-vitro series that would otherwise need many small vials. The labelled amount is a nominal content; a measured value belongs only on a batch report, and none is posted yet for this strength.

Is there a COA for GLP-3 60mg?

Not yet. A Janoshik report exists for a 10 mg vial lot; it does not cover a 60 mg lot and is not shown here. When a 60 mg batch report is issued it will be embedded on this page.

Is GLP-3 60mg for human use?

No. Research-grade material for laboratory use only; not for human or animal consumption. Retatrutide is unapproved everywhere, its phase 3 trials report frequent gastrointestinal adverse events (PMIDs 42250575, 42810372), a 2026 case report describes a hospital admission after an online-sourced product (PMID 42669023), and Shop Peptides Online provides no dosing or administration guidance.

References

1. Coskun T, Urva S et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. PMID 35985340
2. Bajaj HS, Welch M et al. (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. PMID 42250575
3. Bellido V, le Roux CW et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. PMID 42810372
4. Briand F, Le Cudennec C et al. (2026). Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring). PMID 41741376
5. Ding M, Li X et al. (2026). Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. iScience. PMID 42630988
6. Carneiro GRA, da Costa Nunes IK et al. (2026). Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. Rapid Commun Mass Spectrom. PMID 42745421
7. Branine N (2026). Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. PMID 42669023

Sold for laboratory research only and not for human or animal consumption. The description above identifies the material and cites the published literature on the compound without claiming any effect of, or safety for, the material sold.